J&J Will Pay $7.8M To Exit Ark. Risperdal Marketing Suit

A Johnson & Johnson unit has agreed to pay $7.75 million to settle a lawsuit over its marketing of the antipsychotic drug Risperdal to Arkansas doctors, a little more than a...

Already a subscriber? Click here to view full article